NetworkNewsBreaks – Translate Bio Inc. (NASDAQ: TBIO) Closes $275.2M Underwritten Public Offering
Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (“mRNA”) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, has closed an underwritten public offering of 12,506,811 shares of its common stock. According to the update, Translate Bio issued and sold 5,681,819 shares and an existing stockholder, Shire Human Genetic Therapies, Inc. (Shire), a subsidiary of Takeda Pharmaceutical Company Limited, sold 6,824,992 shares. Each of the shares were sold at the public offering price of $22.00, resulting in the gross proceeds of approximately $275.2 million. Translate Bio will not receive proceeds…







